Extracellular vesicles in atopic dermatitis: unraveling pathogenic mediators and engineering therapeutic vectors
By
Wei-Zhen Tang
Chong-Yi Liao
Hong-Yu Xu
Wen-Ting Huang
Zhi-Xian Wu
Tong-Yu Chen
Tai-Hang Liu
Yong-Heng Wang
May 25, 2026
Clinical Scorecard: Role of Extracellular Vesicles in Atopic Dermatitis: Identifying Pathogenic Factors and Developing Therapeutic Delivery Systems
At a Glance
Category Detail
Condition Atopic Dermatitis (AD) Key Mechanisms Epidermal barrier defects, immune dysregulation, microbial imbalance Target Population Patients with Atopic Dermatitis, including children and adults Care Setting Dermatological clinical practice
Key Highlights
AD is characterized by intense pruritus and recurrent skin lesions. Pathogenesis involves a triple hit: barrier dysfunction, dysbiosis, and immune dysregulation. Extracellular vesicles (EVs) play a dual role in AD pathophysiology and treatment. Therapeutic EVs show potential for multipathway immunomodulation. Challenges include standardization of EV preparation and characterization. Guideline-Based Recommendations
Diagnosis
Clinical diagnosis based on symptoms and history. Consideration of genetic predisposition and IgE levels. Management
Topical corticosteroids for acute inflammation. Topical emollients to restore barrier function. Systemic immunosuppressants for moderate-to-severe cases. Monitoring & Follow-up
Regular assessment of skin condition and treatment response. Monitoring for side effects of systemic therapies. Risks
Potential side effects from systemic immunosuppressants. Risk of skin infections due to barrier dysfunction. Patient & Prescribing Data
Individuals with moderate-to-severe Atopic Dermatitis.
Targeted biologics like Dupilumab are emerging as effective treatments.
Clinical Best Practices
Implement long-term disease control strategies. Focus on relapse prevention and symptom relief. Utilize a multidisciplinary approach for comprehensive care. Related Resources & Content
